|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00006072 |
|
Date of registration:
|
25/07/2000 |
|
Primary sponsor: |
|
|
Public title:
|
A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
July 2000 |
|
Target sample size:
|
|
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00006072 |
|
Study type:
|
Interventional |
|
Study design:
|
Masking: Open Label, Primary Purpose: Treatment
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of characteristic peripheral neuropathy by appropriate history, physical
examination, nerve conduction findings and serum autoantibodies.
- Serum anti-GM1 on anti-MAG antibodies present at high titers in serum, continued by
testing in the neuromuscular clinical laboratory at Washington University.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Peripheral Neuropathy
|
|
Intervention(s)
|
|
Drug: Rituxan
|
|
Secondary ID(s)
|
|
M01RR00036
|
|
NCRR-M01RR00036-0690
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|